![](/img/cover-not-exists.png)
749 A novel primeboost therapeutic vaccine induces sustained seroconversion at 52 weeks in patients with HBeAg+ chronic hepatitis B: A phase IIA clinical trial
J. Schneider, W. Halota, D. Delic, Z. Nesic, D. Prokopowicz, R. Flisiak, J. Kuydowicz, M. Jankowski, J. Cianciara, T. Mach, R. Modrzewska, M. Fabri, D. Tomic, A. Horban, W. Krvcka, M. CrippsVolume:
44
Year:
2006
Language:
english
DOI:
10.1016/s0168-8278(06)80750-6
File:
PDF, 176 KB
english, 2006